Menu
Cell and gene therapies will reshape healthcare—but when?
Under the stewardship of The Economist’s editorial team, this event convened industry leaders and healthcare stakeholders to debate the challenges of introducing advanced therapies into the mainstream. It discussed changes in regulatory landscapes, delivery models, structuring clinical trials and gathering real-world evidence that can improve patient access while ensuring companies maintain a competitive edge.
Industry leaders and healthcare stakeholders joined us in Brussels to discuss barriers to advancing these innovative therapies and how to improve patient access.
